As a medical company, working with key opinion leaders is essential to the success of your clinical research. But how do you build your KOL research team?
Chimeric antigen receptor (CAR) T cell therapy is an arising and extremely promising cellular immunotherapy approach to treat cancer. This innovative approach takes advantage of the characteristics of T cells, which are a key component of our immune system. These T cells, hundreds of billions of which circulate through our bodies at any given time, are capable of detecting and destroying cells that have been damaged, infected with viruses, or malignant.
Cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in every six deaths. The burden of cancer continues to grow globally, exerting tremendous physical, emotional, and financial strain on individuals, families, communities as well as healthcare systems.